Company description

AFMD, also known as Affimed NV, is a biopharmaceutical company that focuses on developing innovative treatments for patients with cancer and other serious diseases. Founded in 2000, AFMD is headquartered in Heidelberg, Germany, with a research facility in Princeton, New Jersey. The company specializes in creating targeted immunotherapy treatments that harness the power of the body's own immune system to fight diseases. Their lead product candidate, AFM13, is being developed for the treatment of Hodgkin lymphoma and CD30-positive lymphomas. AFMD also has partnerships with other biopharmaceutical companies to further expand their research and development initiatives. With a dedicated team of scientists and clinicians, AFMD is committed to improving the lives of patients by bringing groundbreaking therapies to the market. They continue to strive towards their mission of becoming a leader in the field of immunotherapy and providing hope for patients suffering from devastating diseases.